全文获取类型
收费全文 | 24585篇 |
免费 | 2033篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 263篇 |
儿科学 | 586篇 |
妇产科学 | 301篇 |
基础医学 | 3383篇 |
口腔科学 | 532篇 |
临床医学 | 3071篇 |
内科学 | 5507篇 |
皮肤病学 | 495篇 |
神经病学 | 2295篇 |
特种医学 | 897篇 |
外国民族医学 | 3篇 |
外科学 | 3646篇 |
综合类 | 275篇 |
现状与发展 | 1篇 |
一般理论 | 10篇 |
预防医学 | 1616篇 |
眼科学 | 411篇 |
药学 | 1583篇 |
中国医学 | 70篇 |
肿瘤学 | 1794篇 |
出版年
2023年 | 145篇 |
2022年 | 130篇 |
2021年 | 505篇 |
2020年 | 399篇 |
2019年 | 612篇 |
2018年 | 739篇 |
2017年 | 553篇 |
2016年 | 575篇 |
2015年 | 715篇 |
2014年 | 914篇 |
2013年 | 1221篇 |
2012年 | 1826篇 |
2011年 | 1980篇 |
2010年 | 1016篇 |
2009年 | 988篇 |
2008年 | 1502篇 |
2007年 | 1535篇 |
2006年 | 1431篇 |
2005年 | 1440篇 |
2004年 | 1297篇 |
2003年 | 1139篇 |
2002年 | 1169篇 |
2001年 | 292篇 |
2000年 | 254篇 |
1999年 | 289篇 |
1998年 | 305篇 |
1997年 | 250篇 |
1996年 | 210篇 |
1995年 | 198篇 |
1994年 | 176篇 |
1993年 | 140篇 |
1992年 | 197篇 |
1991年 | 187篇 |
1990年 | 161篇 |
1989年 | 168篇 |
1988年 | 171篇 |
1987年 | 164篇 |
1986年 | 168篇 |
1985年 | 168篇 |
1984年 | 125篇 |
1983年 | 106篇 |
1982年 | 120篇 |
1981年 | 112篇 |
1980年 | 98篇 |
1979年 | 82篇 |
1978年 | 76篇 |
1977年 | 71篇 |
1976年 | 62篇 |
1975年 | 56篇 |
1974年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
2.
3.
4.
5.
6.
7.
Karis Bennett Tanner Vincent Sumathilatha Sakthi-Velavan 《Clinical anatomy (New York, N.Y.)》2022,35(1):52-64
The patellar ligament (PL) is an epiphyseal ligament and is part of the extensor complex of the knee. The ligament has gained attention due to its clinical relevance to autograft and tendinopathy. A variety of anatomical variations of the PL such as aplasia, numerical variations, and vascularity are being reported recently by clinicians and anatomists. The aim of this literature was to review the available literature to provide a consensus regarding anatomic variations of the PL, neurovasculature surrounding the PL, histology of the PL, and various aspects of PL measurements with relevance to the surgical considerations and sex and age-related differences. A narrative review of the patellar ligament was performed by conducting a detailed literature search and review of relevant articles. A total of 90 articles on the patellar ligament were included and were categorized into studies based on anatomical variations, neurovasculature, morphometrics, microanatomy, sex and age-related difference, and ACL reconstruction. The anatomical variations and morphometrics of the PL were found to correlate with the frequency of strain injuries, tendinopathy, and efficacy of the PL autograft in anterior cruciate ligament reconstruction. The sex differences in PL measurements and the effect of estrogen on collagen synthesis explained a higher incidence of patellar tendinopathy in women. An awareness of its variations enables careful selection of surgical incisions, thereby avoiding complications related to nerve injury. Accurate knowledge of the PL microanatomy assists in understanding the mechanism of ligament degeneration, rupture, autograft harvesting, and ligamentization results. 相似文献
8.
Brendan Le Dar Tatiana Victoni Aude Bodin Manuel Vlach Elise Vene Pascal Loyer Vincent Lagente Thomas Gicquel 《Fundamental & clinical pharmacology》2019,33(1):63-74
Alcohol consumption is considered to be the third leading cause of death in the United States. In addition to its direct toxicity, ethanol has two contrasting effects on the immune system: the nucleotide oligomerization domain‐like receptor pyrin domain‐containing‐3 (NLRP3) inflammasome is inhibited by acute ethanol exposure but activated by chronic ethanol exposure. Purinergic receptors (especially the P2X7 receptor) are able to activate the NLRP3 inflammasome and are involved in many ethanol‐related diseases (such as gout, pulmonary fibrosis, alcoholic steatohepatitis, and certain cancers). We hypothesized that ethanol regulates purinergic receptors and thus modulates the NLRP3 inflammasome's activity. In experiments with monocyte‐derived macrophages, we found that interleukin (IL)‐1β secretion was inhibited after 7 h of exposure (but not 48 h of exposure) to ethanol. The disappearance of ethanol's inhibitory effect on IL‐1β secretion after 48 h was not mediated by the upregulated production of IL‐1β, IL‐1α, IL‐6 or the inflammasome components NLRP3, apoptosis‐associated speck‐like protein containing a caspase recruitment domain, and caspase 1. P2X7R expression was upregulated by ethanol, whereas expression of the P2X4 and P2X1 receptors was not. Taken as a whole, our results suggest that ethanol induces NLRP3 inflammasome activation by upregulating the P2X7 receptor. This observation might have revealed a new mechanism for inflammation in ethanol‐related diseases. 相似文献
9.